Literature DB >> 1346235

Hyperthyroidism due to inappropriate secretion of thyrotropin in 10 patients.

A G Wynne1, H Gharib, B W Scheithauer, D H Davis, S L Freeman, E Horvath.   

Abstract

PURPOSE: The syndrome of inappropriate thyroid-stimulating hormone (TSH) secretion, characterized by elevated serum free thyroxine and triiodothyronine levels in association with measurable serum TSH concentrations, remains an uncommon cause of hyperthyroidism that is being recognized with increasing frequency. The hyperthyroidism may be due to either neoplastic pituitary TSH secretion or selective pituitary resistance to thyroid hormone. In an effort to better understand this rare cause of hyperthyroidism, we undertook a retrospective analysis of our institution's experience with this condition. PATIENTS: We reviewed our cumulative experience (10 patients) with hyperthyroidism due to the syndrome of inappropriate secretion of TSH.
RESULTS: Six patients were diagnosed with TSH-secreting pituitary adenomas and four were found to have selective pituitary resistance to thyroid hormone. One patient with tumor had a TSH-secreting pituitary adenoma in the setting of multiple endocrine neoplasia syndrome. In all patients with tumor, hyperthyroidism was successfully treated with transsphenoidal adenomectomy with or without pituitary radiotherapy. All four patients with pituitary resistance had thyroid ablation or resection prior to their correct diagnosis. Therefore, therapy for this group of patients involved thyroid hormone replacement and efforts to suppress TSH hypersecretion. All 10 patients have done well clinically, with follow-up ranging from 2 weeks to 13 years.
CONCLUSIONS: Adequate treatment exists for the two primary causes of TSH hypersecretion. TSH-secreting pituitary adenomas are treated with surgery and, if necessary, adjuvant pituitary radiotherapy. The results are generally good if the tumor is diagnosed and treated at an early stage. Primary therapy for hyperthyroidism due to selective pituitary resistance to thyroid hormone is aimed at suppression of pituitary TSH hypersecretion. The evaluation of any patient with hyperthyroidism must be thorough and, in some cases, should include measurement of TSH to determine the presence of inappropriate secretion. Eliminating this diagnosis will help avoid improper and potentially harmful treatment of hyperthyroid patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1346235     DOI: 10.1016/0002-9343(92)90009-z

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  4 in total

1.  Long-term preoperative management of thyrotropin-secreting pituitary adenoma with octreotide.

Authors:  P Iglesias; J J Díez
Journal:  J Endocrinol Invest       Date:  1998-12       Impact factor: 4.256

Review 2.  Clinical use of sensitive assays for thyroid-stimulating hormone.

Authors:  P A Masters; R J Simons
Journal:  J Gen Intern Med       Date:  1996-02       Impact factor: 5.128

3.  An arginine to histidine mutation in codon 311 of the C-erbA beta gene results in a mutant thyroid hormone receptor that does not mediate a dominant negative phenotype.

Authors:  M E Geffner; F Su; N S Ross; J M Hershman; C Van Dop; J B Menke; E Hao; R K Stanzak; T Eaton; H H Samuels
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

4.  A Plurihormonal TSH-Secreting Pituitary Microadenoma: Report of a Case with an Atypical Clinical Presentation and Transient Response to Bromocriptine Therapy.

Authors:  Sergio Zuniga; Victoria Mendoza; Ignacio Felix Espinoza; Arturo Zarate; Macrina Mason; Moises Mercado
Journal:  Endocr Pathol       Date:  1997       Impact factor: 3.943

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.